FBXO3

Across TCGA pan-cancer cohorts, FBXO3 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of FBXO3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where FBXO3 RNA is repressed in tumor relative to normal tissue. In most cancer types FBXO3 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, LIHC, and KICH are the cancer types where FBXO3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXO3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.739	<.001	9	view →
LIHC	Male	All	+0.510	<.001	9	view →
KICH	Male	II,III,IV	−1.136	<.001	8	view →
UCEC	All	All	−0.907	<.001	6	view →
COAD	Female	All	−0.392	.019	4	view →
LUAD	All	III,IV	−0.383	.002	4	view →
READ	All	All	−0.621	.001	3	view →
CHOL	All	All	+0.832	.005	2	view →
KIRP	Male	All	−0.324	.024	2	view →
PRAD	All	All	−0.210	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

FBXO3–THCA

Open the THCA breakdown →